

# Effect of phenolic acids on functions of rat aorta, vas deferens and on metabolic changes in streptozotocin-induced diabetes

Nurcan Bektas, Yusuf Ozturk

Department of Pharmacology,  
Faculty of Pharmacy, Anadolu  
University, Tepebasi TR-26470,  
Eskisehir, Turkey

Received: 05-10-2011

Revised: 05-10-2011

Accepted: 17-12-2011

Correspondence to:

Dr. Nurcan Bektas,  
E-mail: nurcanbektas@anadolu.  
edu.tr

## ABSTRACT

**Objectives:** This study aimed to investigate the effects of antioxidant treatment on streptozotocin (STZ)-induced diabetic metabolic and smooth muscle (SM) complications in rats.

**Materials and Methods:** Threeweeks after STZ injection (i.v.), vehicle, *p*-OH benzoic (*p*-OHBA), protocatechic (PA) and gallic acids (GA) were separately administered (10 mg/kg each, i.p.) to the rats everyday for 3 weeks. Metabolic functions were observed regularly. The rats in all groups were sacrificed and aorta and Vas deferens were dissected. The responses of isolated organs to agonists (acetylcholine and phenylephrine) were recorded.

**Results:** Protocatechic acid prevented increase in food consumption and feces output significantly. The responses of isolated organs to agonists increased in the STZ-diabetic rats. The test drugs either prevented, exacerbated or did not affect the SM changes in the STZ-diabetic rats.

**Conclusions:** It was concluded that *p*-OHBA, PA and GA may cause effects independently of their antioxidant effect and/or of diabetic complications. They may exhibit pro-oxidant activities in the experimental conditions applied.

**KEY WORDS:** Aorta, diabetic complications, oxidative stress, phenolic acids, Vas deferens

## Introduction

Free radicals have an important role in the pathogenesis of diabetes mellitus (DM). Oxidative stress (OS) and/or decreased antioxidant defenses are believed to play a critical role in the contribution of smooth muscle (SM) complications in vascular and reproductive system in DM.<sup>[1,2]</sup> It has been reported that the increasing of OS during diabetes, largely due to hyperglycemia, causes neuropathy as a diabetic complication.<sup>[3]</sup> As autonomic nerves are highly integrated with SM cells in various physiological systems, autonomic neuropathy due to experimental diabetes may cause consequent changes in SMs.<sup>[4,5]</sup> Conflicting responses to several agonists in SMs of experimentally diabetic animals have been reported suggesting the defective contractile process of SMs.<sup>[4]</sup>

Anomalies of function and structure of autonomic nerves induced with augmented OS may cause erectile dysfunction,

impaired ejaculation and decreased fertility in diabetic animals.<sup>[6]</sup> Complications of the reproductive system may be a distressing feature for the male patients with long-term DM. Cardiovascular complications are also common.<sup>[7]</sup>


Treatment with antioxidants may prevent or ameliorate abnormal function and biochemistry of nerve and protect nerves against to free radicals damage.<sup>[8]</sup> Consequently it is postulated that these agents can prevent diabetic complications.<sup>[9]</sup> Phenolic acids (PhA) are well-known antioxidants, and also their antidiabetic activities have been reported in many studies.<sup>[10,11]</sup> The antioxidant activity of PhA correlated positively with the number of hydroxyl groups bonded to aromatic ring.<sup>[12]</sup>

In this study, we attempted to identify the possible effects of 3-week treatment with 10 mg/kg *p*-OH benzoic acid (*p*-OHBA), protocatechic acid (PA) and gallic acid (GA), which have antioxidant activities with increasing potency order related to their hydroxyl number, on diabetic SMs complications developed in aorta and vas deferens. Experimental procedures were applied on the isolated organs which were isolated from 6-week streptozotocin (STZ)-diabetic rats.

## Materials and Methods

### Animals

Male Wistar rats (250–300 g) were used in this study. The animals were maintained on 12 h light/12 h dark cycle and at

Access this article online	
Website: <a href="http://www.ijp-online.com">www.ijp-online.com</a>	Quick Response Code:
DOI: 10.4103/0253-7613.93845	

24 ± 1°C with standard pellet diet and tap water ad libitum. Animal care and research protocols were based on the principles and guidelines adopted by the Guide for the Care and Use of Laboratory Animals (NIH publication No: 85-23, revised in 1985) and approved by the Local Ethics Committee of Osmangazi University, Eskişehir.

### Chemicals

The chemical used included streptozotocin (Sigma, St. Louis, USA), Citric acid (Merck, Darmstadt, Germany), Trisodium citrate (Merck), *p*-OHBA (Sigma), PA (Sigma), GA (Sigma), Phenylephrine.HCl (Sigma), Acetylcholine.HCl (Sigma), NaCl (Merck), KCl (Merck), MgCl<sub>2</sub> (Merck), KH<sub>2</sub>PO<sub>4</sub> (Sigma), NaHCO<sub>3</sub> (Merck), Glucose.H<sub>2</sub>O (Merck), CaCl<sub>2</sub>.2H<sub>2</sub>O (Merck).

### Induction of Diabetes and Experimental Groups

The animals were injected with STZ in a single i.v. injection (50 mg/kg in 0.1 M citric acid buffer, pH 4.5, i.v.) to induce diabetes.<sup>[13]</sup> After 73 hours of injection, blood glucose levels were measured by Glukotrend® (Roche, Switzerland) and the rats with a blood glucose level more than 300 mg/dl were selected. The other group was injected with citric acid buffer (i.v.) only to serve as non-diabetic control group. The diabetic rats were divided into 4 groups. The 1<sup>st</sup> group was used as STZ-diabetic control and injected with saline (i.p.). Three-weeks after induction of diabetes, the rats in the 2<sup>nd</sup> group were injected with (i.p.) 10 mg/kg *p*-OHBA, 3<sup>rd</sup> group was injected with 10 mg/kg PA and the last group was injected with 10 mg/kg GA everyday for 3-weeks. Blood glucose levels were measured at same hours in every week.

### Metabolic-cages Measurements

The rats in all groups were individually housed in metabolic-cages (Ugo-basile, 41700, Italy) 3 weeks after induction of diabetes. Water and food intake, urine and feces excretion were monitored during 3 weeks. The weights of rats were also measured in every week.

### Isolated Organ Bath Experiments

Both the diabetic and non-diabetic rats were sacrificed by cervical dislocation 6 weeks after induction of diabetes. Thoratic aorta and vas deferens were rapidly removed and placed in Krebs-Henseleit solution (KHS) (g/L: NaCl-6.9544; KCl-0.3504; MgCl<sub>2</sub>-0.0952; KH<sub>2</sub>PO<sub>4</sub>-0.1633; NaHCO<sub>3</sub>-2.1002; Glucose.H<sub>2</sub>O-2.20; CaCl<sub>2</sub>.2H<sub>2</sub>O-0.36) (pH=7.4). After cleaning of adhering fat and connective tissues, aorta ring was mounted with a resting tension of 1.0 g and vas deferens was mounted with a resting tension of 0.5 g in an isolated organ bath (Ugo-basile, 4050, Italy) containing 10 ml KHS, aerated with mixture of 95%O<sub>2</sub> and 5% CO<sub>2</sub> at 37°C.<sup>[14,15]</sup> The responses of isolated organs were recorded isometrically using a force-displacement transducer (Ugo-basile, 7003, Italy) connected to a pen recorder (Ugo-basile, 7070, Italy). After 1-h incubation period, concentration-response relationships of aorta were obtained with doses of 10<sup>-9</sup>-10<sup>-3</sup> M phenylephrine (PE). After resting period, aorta pre-contracted with PE (10<sup>-4</sup> M) to relax in response to 10<sup>-9</sup>-10<sup>-3</sup> M acetylcholine (ACh). The vas deferens was firstly contracted with 10<sup>-9</sup>-10<sup>-3</sup> M ACh and then after resting period it was exposed to doses of 10<sup>-9</sup>-10<sup>-3</sup> M PE.

### Statistical Analysis

All isolated organ responses were expressed as apparent affinity constant (pD<sub>2</sub>) and percentage of corresponding maximal

responses to each agonist (E<sub>max</sub>). The statistical analyses were performed by one-way ANOVA, followed by Tukey's multiple comparison tests for isolated-organ bath experiments, and Student 't' test for metabolic-cage measurements. The statistical analyses were carried out using GraphPad Prism version 5.0 and Microsoft Office Excel. The values were expressed as the mean ± S.E.M. to show variation in groups. P ≤ 0.05 was considered statistically significant.

## Results

### Blood Glucose Levels

Blood glucose levels of all groups were observed to be significantly higher than the non-diabetic group and *p*-OHBA, PA and GA did not normalize hyperglycemia in STZ-induced diabetes [Figure 1].

### Metabolic-Cage Measurements

*p*-OHBA, PA and GA did not change polyuria and polydipsia. However, PA decreased the amounts of food intake and feces output significantly although *p*-OHBA and GA did not affect these parameters [Figure 2]. PA prevented weight loss when compared to *p*-OHBA and GA, but this effect was not significant [Figure 3].


It was concluded that the positive effect of PA may be through different mechanisms other than diabetogenic mechanisms and/or antioxidant effect; because the other symptoms were not affected by PA and the other test drugs did not change these parameters.

### Isolated Organ Bath Experiments

#### Isolated aorta

Table 1 presents pD<sub>2</sub> and E<sub>max</sub> values which were calculated from contractile responses of aorta to PE and relaxation responses to ACh. pD<sub>2</sub> of STZ-diabetic group was found to be unchanged. pD<sub>2</sub> of *p*-OHBA-treated group which was contracted with PE decreased according to non-diabetic control group; however, treatment with PA and GA did not alter this value. Also in PE-contracted group, it was observed that E<sub>max</sub> of STZ-diabetic group increased significantly when compared with the non-diabetic group. *p*-OHBA prevented this alteration partially while PA improved it. However, GA normalized this value even reduced it insignificantly under non-diabetic group' value.

**Figure 1:** Blood glucose levels of non-diabetic control (C), STZ-diabetic control (STZ), *p*-OHBA-treated (STZ+*p*-OHBA), PA-treated (STZ+PA) and GA-treated (STZ+GA) rats, \*\*\*P<0.001; significance relative to C, (n=6)




Diabetes, induced by STZ, and administration of *p*-OHBA and GA to STZ-diabetic rats aorta didnot cause alteration in relaxation responses of aorta. However, only  $pD_2$  value decreased in PA-treated group.

*Isolated vas deferens*

Table 2 summarizes  $pD_2$  and  $E_{max}$  values calculated from contractions of groups in response to PE and ACh. There was no significant difference between groups in  $pD_2$  values which

were calculated from contractile response of vas deferens to PE. However,  $E_{max}$  values demonstrated that STZ-diabetic group exhibited an increase in contraction of PE when compared with non-diabetic group.  $pD_2$  values of STZ-diabetic and PA-treated groups which were contracted with ACh were found to be unchanged. Administration of *p*-OHBA and GA to the diabetic-rats increased the  $pD_2$  values significantly when compared to non-diabetic and STZ-diabetic groups. Statistically significant increases were observed in the  $E_{max}$  of

**Figure 2:** Water and food intake amount, and urine and feces output of non-diabetic control (C), STZ-diabetic control (STZ), *p*-OHBA-treated (STZ+*p*-OHBA), PA-treated (STZ+PA) and GA-treated (STZ+GA) rats, (n=6)



**Table 1:**

$pD_2$  and  $E_{max}$  values obtained from non-diabetic control (C), STZ-diabetic control (STZ), *p*-OHBA-treated (STZ+*p*-OHBA), PA-treated (STZ+PA) and GA-treated (STZ+GA) rats aorta response to PE and pre-contracted aorta response to ACh

	Aorta response to PE		Pre-contracted aorta response to Ach	
	$pD_2 \pm S.E.M.$	$E_{max} \pm S.E.M.$	$pD_2 \pm S.E.M.$	$E_{max} \pm S.E.M.$
C	7.48 ± 0.20	100 ± 0.00	6.69 ± 0.14	58.39 ± 6.65
STZ	7.31 ± 0.09	*121.60 ± 4.36	6.43 ± 0.15	58.02 ± 2.30
STZ+ <i>p</i> -OHBA	*6.89 ± 0.10	109.60 ± 8.09	7.01 ± 0.27	68.85 ± 4.90
STZ+PA	7.23 ± 0.14	**129.40 ± 7.08	*6.07 ± 0.12	59.77 ± 2.87
STZ+GA	7.18 ± 0.20	##99.25 ± 6.38	6.59 ± 0.18	53.83 ± 6.44

\* $P < 0.05$ , \*\* $P < 0.01$ , significance relative to C, ## $P < 0.01$ , significance relative to STZ, (n=6)


**Table 2:**

$pD_2$  and  $E_{max}$  values obtained from non-diabetic control (C), STZ-diabetic control (STZ), *p*-OHBA-treated (STZ+*p*-OHBA), PA-treated (STZ+PA) and GA-treated (STZ+GA) rats Vas deferens response to PE and ACh

	Vas deferens response to PE		Vas deferens response to ACh	
	$pD_2 \pm S.E.M.$	$E_{max} \pm S.E.M.$	$pD_2 \pm S.E.M.$	$E_{max} \pm S.E.M.$
C	5.63 ± 0.04	100 ± 0.00	3.84 ± 0.04	100 ± 0.00
STZ	5.76 ± 0.07	*122.60 ± 5.49	4.03 ± 0.02	***155.40 ± 6.36
STZ+ <i>p</i> -OHBA	5.85 ± 0.07	111 ± 7.15	***##4.32 ± 0.09	***#136.80 ± 4.84
STZ+PA	5.58 ± 0.08	115.50 ± 5.98	3.97 ± 0.05	###112.70 ± 6.09
STZ+GA	5.52 ± 0.08	115.50 ± 5.10	***##4.48 ± 0.14	###91.93 ± 5.01

\* $P < 0.05$ , \*\*\* $P < 0.001$ , significance relative to C, # $P < 0.05$ , ## $P < 0.01$ , ### $P < 0.001$ , significance relative to STZ, (n=6)

**Figure 3:** Weight loss of non-diabetic control (C), STZ-diabetic control (STZ), *p*-OHBA-treated (STZ+*p*-OHBA), PA-treated (STZ+PA) and GA-treated (STZ+GA) rats, (*n*=6)



STZ-diabetic group when compared to non-diabetics. *p*-OHBA decreased  $E_{max}$  significantly as compared to STZ-diabetic group but could not normalize it. PA and GA normalized the value, the  $E_{max}$  of GA-treated group decreased when compared to non-diabetic group.

## Discussion

STZ-induced diabetes results in changes in vascular reactivity to both vasoconstrictor and vasodilator agents. However, the results are conflicting, as increased, decreased or unchanged responses to same type of agonists have been observed in various studies.<sup>[4]</sup> It was reported that enhanced contractile responses of STZ-diabetic rat aorta to  $\alpha$ -adrenergic agonists as noradrenaline are largely dependent on the presence of extracellular  $Ca^{++}$ , increased adrenergic stimulation, phosphoinositide metabolism,  $Ca^{++}$  channels sensitivity, deficiency of endothelial activity and/or decreased calmodulin levels.<sup>[16-18]</sup> In this study, by evaluation of increased response to PE of STZ-diabetic rat aorta, it was supposed that 6-week STZ-induced diabetes changed the  $\alpha$ -adrenergic receptor number and/or the mechanisms which were mentioned above without changing receptor affinity. However, muscarinic receptor affinity, number or post-receptor pathways remained unchanged.

Experimental diabetes also causes alterations in responses of Vas deferens to certain agonists.<sup>[4]</sup> It was reported that impaired responses to adrenergic nerve stimulation and hypersensitivity to ACh, noradrenaline and PE were observed in diabetic-rats. The enhanced  $\alpha$ -adrenergic responsiveness of diabetic-rat Vas deferens was attributed to defective signal transduction mechanisms rather than an increase in the affinity or number of adrenoceptors.<sup>[19]</sup> In fact, altered metabolic product profile of arachidonic acid, hyperactivity of  $Na^+$ ,  $K^+$ -ATP<sub>ase</sub>, calcium channels and levels were reported as responsible mechanisms for the increased contractions in Vas deferens.<sup>[4]</sup> Another diabetic changes in the rat Vas deferens is the increased muscarinic responsiveness associated with the increase in muscarinic receptor density. Up regulation of  $M_2$ -muscarinic receptors was shown in STZ-diabetes.<sup>[20]</sup> As in many studies, in this study,  $\alpha$ -adrenergic and muscarinic responsiveness in Vas deferens from 6-week STZ-diabetic rats increased significantly and it was attributed to increase in the number of receptors and activity of the post-receptor mechanisms as mentioned above since there was no changes in receptor affinity. Our results

are compatible with some studies while conflicting with some other. The reasons for this controversy are not apparent but are generally attributed to differences in duration of diabetes, animal strains and techniques applied for the measuring and expressing contractile force. However, underlying causes of augmented contractile responses of Vas deferens to PE and ACh and aorta to PE require further investigations.

There has been a suggestion that antioxidants might be effective in preventing diabetic complications since free radicals have an important role in the pathogenesis of diabetes and its complications.<sup>[21]</sup> On the contrary, in this study, *p*-OHBA, PA and GA showed conflicting effects in STZ-diabetic aorta and Vas deferens. The test drugs either prevented or exacerbated or did not affect the SM changes in the STZ-diabetic rats, and sometimes, they affected the SM activity which did not change through diabetes when compared to the non-diabetic rats. These effects of test drugs are not generally related with -OH number that is attributed to these PhA possesses different polarities so the rate of their migration into the cell is different. Based on these results, it was concluded that the demonstrated preventive effects of test drugs developed independently from antioxidant potential and restoration of diabetic complications. Moreover, since the impaired effects of used antioxidants were observed, it was thought that these antioxidants may act like pro-oxidant in our experiment conditions. Pro-oxidant effects of various PhA were demonstrated in different conditions.<sup>[22,23]</sup> It is known that pro-oxidant activity of phenolics increases in presence of redox active metal ions such as  $Fe^{++}$  and  $Cu^{++}$  and levels of  $Fe^{++}$ ,  $Cu^{++}$ , and  $Zn^{++}$  ions change in diabetic conditions.<sup>[24,25]</sup> Polyphagia and metabolic changes in diabetic-rats cause accumulation of metal ions in tissues.<sup>[26]</sup> These metabolic changes were observed in our study and changed levels of all of these ions may have affected test drugs actions in this study.

On the basis of these findings and related studies, it seems possible that *p*-OHBA, PA and GA may exhibit improving or impairing effects independently from their antioxidant power and from mechanisms of diabetic complications. Furthermore, they may exhibit pro-oxidant activities in the experimental conditions applied, since the levels of  $Fe^{++}$  and  $Cu^{++}$  increase and  $Zn^{++}$  decrease in diabetic conditions. However, detailed investigations are needed to clarify the occurrence of the conditions when antioxidants act as pro-oxidants in the same experimental design in this study.

## References

1. Costacou T, Zgibor JC, Evans RW, Tyurina YY, Kagan VE, Orchard TJ. Antioxidants and coronary artery disease among individuals with type-1-diabetes: Findings from the Pittsburgh Epidemiology of diabetes complications study. *J Diabetes Complications* 2006;20:387-94.
2. Thorve VS, Kshirsagar AD, Vyawahare NS, Joshi VS, Ingale KG, Mohite RJ. Diabetes-induced erectile dysfunction: Epidemiology, pathophysiology and management. *J Diabetes Complications* 2011;25:129-36.
3. Valensi P, Devehat CL, Richard JL, Farez C, Khodabandehlou T, Rosenbloom RA, et al. A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy: A preliminary report. *J Diabetes Complications* 2005;19:247-53.
4. Ozturk Y, Altan VM, Yildizoglu-Ari N. Effects of experimental diabetes and insulin on smooth muscle functions. *Pharmacol Rev* 1996;48:69-112.
5. Zhao Y, Ye W, Boye KS, Holcombe JH, Hall JA, Swindle R. Prevalence of other diabetes-associated complications and comorbidities and its impact on health



- care charges among patients with diabetic neuropathy. *J Diabetes Complications* 2010;24:9-19.
6. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. *Diabetes Care* 2003;5:1553-79.
  7. Shirpoor A, Salami S, Khadem-Ansari MH, Ilkhanizadeh B, Pakdel FG, Khademvatani K. Cardioprotective effect of vitamin E rescues of diabetes-induced cardiac malfunction, oxidative stress, and apoptosis in rat. *J Diabetes Complications* 2009;23:310-6.
  8. Karasu C, Dewhurst M, Stevens EJ, Tomlinson DR. Effects of anti-oxidant treatment on sciatic nerve dysfunction in streptozotocin-diabetic rats: Comparison with essential fatty acids. *Diabetologia* 1995;38:129-34.
  9. Montonen J, Knekt P, Järvinen R, Reunanen A. Dietary antioxidant intake and risk of type 2 diabetes. *Diabetes Care* 2004;27:362-6.
  10. Mukherjee PK, Maiti K, Mukherjee K, Houghton PJ. Leads from Indian medicinal plants with hypoglycemic potentials. *J Ethnopharmacol* 2006;106:1-28.
  11. Aslan M, Deliorman-Orhan D, Orhan N, Sezik E, Yesilada E. *In vivo* antidiabetic and antioxidant potential of *Helichrysum plicatum* ssp. *plicatumcapitulums* in streptozotocin induced-diabetic rats. *J Ethnopharmacol* 2007;109:54-9.
  12. Peyrat-Maillard MN, Bonnely S, Berset C. Determination of the antioxidant activity of phenolic compounds by coulometric detection. *Talanta* 2000;51:709-16.
  13. Oh TK, Li MZ, Kim ST. Gene therapy for diabetes mellitus in rats by intramuscular injection of lentivirus containing insulin gene. *Diabetes Res Clin Pract* 2006;71:233-40.
  14. Kamata K, Kirisawa H. Changes in electrophysiological properties and noradrenaline response in Vas deferens of diabetic-rats. *Eur J Pharmacol* 1998;350:237-41.
  15. Ersoy S, Orhan I, Turan NN, Sahan G, Ark M, Tosun F. Endothelium-dependent induction of vasorelaxation by *Melissa officinalis* L. ssp. *officinalis* in rat isolated thoracic aorta. *Phytomedicine* 2008;15:1087-92.
  16. Ozcelikay AT, Pekiner C, Ari N, Ozturk Y, Altan VM. The effect of vanadyl treatment on vascular responsiveness of streptozotocin-diabetic rats. *Diabetologia* 1994;37:572-8.
  17. Abebe W, Haris KH, Macleod KM. Enhanced contractile responses of arteries from diabetic-rats to 1-adrenoceptor stimulation in the absence and presence of extracellular calcium. *J Cardiovasc Pharmacol* 1990;16:239-48.
  18. Ozturk Y, Aydin S, Altan VM, Yildizoglu-Ari N, Ozcelikay AT. Effects of short-and longtermstreptozotocin-diabetes on smooth muscle calmodulin levels. *Cell Calcium* 1994;16:81-6.
  19. Ozturk Y, Aydin S. Effects of streptozotocin-induced diabetes and insulin on calcium responsiveness of the rat Vas deferens. *Life Sci* 2006;78:1084-90.
  20. Longhurst PA. The effect of testosterone or insulin treatment on contractile responses of the rat Vas deferens following castration or streptozotocin-induced diabetes mellitus. *Gen Pharmacol* 1990;21:427-34.
  21. Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: Linking basic science to clinical practice. *Cardiovasc Diabetol* 2005;4:5.
  22. Park S, Lee S. Antioxidant and prooxidant properties of ascorbic acid on hepatic dysfunction induced by cold ischemia/reperfusion. *Eur J Pharmacol* 2008;580:401-6.
  23. Gil-Longo J, González-Vázquez C. Vascular pro-oxidant effects secondary to the autoxidation of gallic acid in rat aorta. *J Nutr Biochem* 2009;21:304-9.
  24. Prat ML, López-González A, Ruiz MA, Barbas C. Ultrasound-assisted extraction for rapid determination of Zn, Cu, Fe, Mg and Mn in liver of diabetic-rats under different antioxidant treatments. *J Pharm Biomed Anal* 2009;49:1040-4.
  25. Zago MP, Oteiza PJ. The antioxidant properties of zinc: Interactions with iron and antioxidants. *Free Radic Biol Med* 2001;31:266-74.
  26. Oster MH, Uriu-Hare JY, Trap CL, Stern JS, Keen CL. Dietary macronutrient composition influences tissue trace element accumulation in diabetic Sprague-Dawley rats. *Proc Soc Exp Biol Med* 1994;207:67-75.

**Cite this article as:** Bektas N, Ozturk Y. Effect of phenolic acids on functions of rat aorta, vas deferens and on metabolic changes in streptozotocin-induced diabetes. *Indian J Pharmacol* 2012;44:184-8.

**Source of Support:** Nil. **Conflict of Interest:** None declared.

Copyright of Indian Journal of Pharmacology is the property of Medknow Publications & Media Pvt. Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.